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Possible role of death receptor-mediated
apoptosis by the E3 ubiquitin ligases Siah2
and POSH
Perry A Christian, Michael V Fiandalo and Steven R Schwarze*
Abstract
Background: A functioning ubiquitin proteasome system (UPS) is essential for a number of diverse cellular
processes and maintenance of overall cellular homeostasis. The ability of proteasome inhibitors, such as Velcade, to
promote extrinsic apoptotic effects illustrates the importance of the ubiquitin proteasome system in the regulation
of death receptor signaling. Here, we set out to define the UPS machinery, particularly the E3 ubiquitin ligases, that
repress apoptosis through the extrinsic pathway. A cell-based genome-wide E3 ligase siRNA screen was established
to monitor caspase-8 activity following the addition of TRAIL.
Results: Data from the high-throughput screen revealed that targeting the RING-finger containing E3 ligase Siah2
as well as the signaling platform molecule POSH (SH3RF1) conferred robust caspase-8 activation in response to
TRAIL stimulus. Silencing Siah2 or POSH in prostate cancer cells led to increased caspase activity and apoptosis in
response to both TRAIL and Fas ligand. The E3 activity of Siah2 was responsible for mediating apoptosis resistance;
while POSH protein levels were critical for maintaining viability. Further characterization of Siah2 revealed it to
function downstream of early death receptor events in the apoptotic pathway. The observed apoptosis resistance
provides one biological explanation for the induction of Siah2 and POSH reported in lung and prostate cancer,
respectively. Expanding on an initial yeast-two-hybrid screen we have confirmed a physical interaction between E3
ligases Siah2 and POSH. Utilizing a yeast-two-hybrid mapping approach we have defined the spacer region of
POSH, more specifically the RPxAxVxP motif encompassing amino acids 601-607, to be the site of Siah2 binding.
Conclusions: The data presented here define POSH and Siah2 as important mediators of death receptor mediated
apoptosis and suggest targeting the interaction of these two E3 ligases is a promising novel cancer therapeutic
strategy.
Background
Tight regulation of apoptosis is essential for maintaining
tissue homeostasis. Altering this balance in favor of
apoptosis resistance is a common feature in cancer cells
[1], and overcoming cell death barriers is a primary goal
of many chemotherapeutic treatments used in the clinic
today. One proven strategy to induce apoptosis is
through blocking components of the ubiquitin protea-
some system (UPS).
The ubiquitin proteasome system is the major cellular
pathway for regulated protein turnover. Ubiquitination
and protein degradation allows the cell to respond
quickly to extra- or intracellular signals, thereby main-
taining cellular homeostasis. The addition of multiple
ubiquitin moieties to a targeted protein “tags” the pro-
tein for degradation by the 26S proteasome. The
mechanism by which multiple ubiquitin molecules are
added to targeted substrates can be depicted as a three-
step process. First, the ubiquitin activating enzyme (E1)
catalyzes the formation of a C-terminal thiol ester in an
ATP dependent reaction. The ubiquitin is then trans-
ferred to an E2 ubiquitin-conjugating enzyme via the
formation of a thiol ester bond. Finally, the ubiquitin
ligase enzymes (E3) catalyze the transfer of ubiquitin
from the E2 to a lysine residue on the targeted protein
via an isopeptide linkage. A polyubiquitinated protein is* Correspondence: steve.schwarze@uky.edu
Markey Cancer Center and the Department of Molecular and Cellular
Biochemistry, University of Kentucky, Lexington, KY 40536, USA
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then recognized by the 19S regulatory subunit of the
26S proteasome and degraded by the 20S core particle.
Several strategies to block UPS components in the
treatment of cancer have been devised. The initial
approach was the development of the 26S proteasome
inhibitor Velcade (bortezomib), which has been shown
to induce apoptosis and is approved to treat multiple
myeloma [2]. Subsequently, investigators have sought
to promote the stability of numerous apoptosis-asso-
ciated proteins, such as the p53 interaction with the
E3 ligase Mdm2 [3]. Preventing proteasomal degrada-
tion of active caspases is another area that has shown
promise. Polyubiquitination and subsequent degrada-
tion of active caspases by the inhibitor of apoptosis
protein (IAP) family can downregulate the apoptotic
response. In some systems, IAP self-ubiquitination and
degradation is required for full apoptosis activation [4],
while in others free Smac/DIABLO released from the
mitochondria can bind IAPs and inhibit their anti-
apoptotic activity [5]. The ability of Smac mimetic
compounds that target IAP activity to sensitize cancer
cells to chemotherapeutic agents is currently being
tested in clinical trials [6].
There are two major apoptotic-inducing pathways,
intrinsic (mitochondrial) and extrinsic (death receptor-
mediated). The involvement of ubiquitination in the reg-
ulation of apoptosis has largely been assessed in the
intrinsic apoptotic pathway (i.e., Mdm2/p53, Smac/IAP).
In contrast, much less is known regarding the ubiquiti-
nation machinery or ubiquitin substrates that regulate
cell-extrinsic apoptosis. Death receptor-mediated apop-
tosis is induced by the binding of death ligands to their
corresponding death receptors at the plasma membrane
[7]. Death ligands are members of the tumor necrosis
factor (TNF) family of ligands such as Fas Ligand (FasL)
and TNF related apoptosis inducing ligand (TRAIL).
Clustering of death receptors upon ligation allows for
the formation of the death inducing signaling complex
(DISC) [8]. Procaspase-8 present at the DISC, and possi-
bly in other high molecular weight aggregates, is autoca-
talytically processed to form an active p10/p18
homodimer [9]. Active caspase-8 can cleave effector cas-
pases-3 and -7, as well as other death substrates, fully
inducing the downstream apoptotic pathway.
Here, using a high throughput siRNA screen we iden-
tified two E3 ubiquitin ligases, Siah2 (Seven in absentia
homologue) and SH3RF1 (SH3 domain containing
RING finger 1, also known as POSH for plenty of SH3
domains), as negative regulators of death receptor
mediated apoptosis through the modulation of caspase-8
activity. We also defined a physical interaction between
these two E3s suggesting Siah2 and POSH may function
through shared or similar signaling pathways to regulate
extrinsic apoptosis.
Results and Discussion
A ubiquitin ligase screen identifies Siah2 and POSH as
regulators of caspase-8 activity
We previously demonstrated the ability of proteasome
inhibition to sensitize cancer cells to death receptor-
mediated apoptosis both in vitro and in vivo [10,11].
The goal of this study was to identify ubiquitin ligases
that could impair death receptor signaling. DU145 pros-
tate cancer cells were selected as a model to address
this question because of their low levels of background
caspase-8 activity. First, to confirm the synergy between
proteasome inhibition and death ligand signaling in the
DU145 line, cells were treated with Velcade (50 nM)
and TRAIL (100 ng/mL) alone or in combination. Cells
treated with the combined Velcade and TRAIL regimen
displayed a significant reduction in cell viability and a
corresponding increase in apoptosis as determined by
annexin V staining (Figure 1a). Next, to identify possible
UPS associated proteins that may be important for
death receptor signaling, an E3 ligase siRNA screen was
performed as outlined (Figure 1b). DU145 cells were
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Figure 1 E3 ubiquitin ligases Siah2 and POSH can regulate
caspase-8 activity. a: (left) MTT viability and (right) annexin V
apoptosis analysis of DU145 cells treated with Velcade (50 nM),
GST-TRAIL (100 ng/mL) or the combination for 24 and 16 hours,
respectively. b: Flow chart illustrating the experimental design of
the E3 ubiquitin ligase screen utilized in this study. c: Representative
screening results showing 90 out of 239 E3 ligases examined in the
siRNA screen. DU145 cells were plated/reverse-transfected for 72
hours and then treated with TRAIL (50 ng/ml) for 16 hours. Caspase-
8 activity was quantified using a luminescent reporter. Values were
normalized by subtracting out the background levels of caspase-8.
The black bar indicates treatment with TRAIL and Velcade. Gray bars
denote each TRAIL treated and siRNA targeted E3. ‘No TRAIL’
indicates no treatment. d: Assessment of Siah2 and POSH silencing
in DU145 cells using qRT-PCR 24 hours post-transfection. All data
are represented as the mean +/- the standard deviation. *P < 0.05,
**P < 0.01, ***P < 0.001 using a two-tailed Student’s t-test.
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concurrently seeded in 96-well plates and reverse-
transfected with siRNA from a E3 ligase library. Follow-
ing a 72-hour incubation, cells were treated with TRAIL
(100 ng/mL) for 16 hours. Cells treated with the combi-
nation of Velcade and TRAIL or left untreated served as
positive and negative controls, respectively. Caspase-8
activity was measured by the addition of a synthetic
pro-luminogenic caspase-8 specific substrate. Results
from our screen demonstrated that targeting of two
E3 ligases, Siah2 and POSH, lead to an significant
(P < 0.01) induction of caspase-8 activity in the presence
of TRAIL (Figure 1c).
The ability of the siRNA pool used in the screen to
reduce Siah2 or POSH mRNA levels was assessed in
DU145 cells. An average knockdown of 95 and 80% was
observed for Siah2 and POSH siRNA pools, respectively
(Figure 1d).
Silencing Siah2 or POSH enhances initiator and effector
caspase activity in response to TRAIL
Although the DU145 cells used above exhibit enhanced
caspase-8 activity in the presence of TRAIL, they are
resistant to cell death. Therefore, PC-3 and PPC-1 pros-
tate epithelial cancer cell models were chosen for subse-
quent analyses based on their partial sensitivity to
TRAIL-induced apoptosis [10]. First, Siah2 and POSH
gene knockdown by siRNA in PC-3 and PPC-1 cells was
determined by qRT-PCR. Over 90% knockdown was
observed in PC-3 cells and 80% silencing in PPC-1 cells
for each gene (Figure 2a).
To determine the biological consequence of Siah2/
POSH silencing on caspase activity, PC-3 cells were trans-
fected with siRNA specific for these two E3 ligases or a
non-targeting control. After 72 hours, transfected cells
were left untreated or treated with TRAIL (100 ng/mL)
for two or four hours to obtain early values for activity of
the extrinsic pathway initiator caspase, caspase-8. TRAIL
treatment induced caspase-8 activity in all samples. Both
Siah2 and POSH repression led to elevated levels of cas-
pase-8 activity over the non-targeting control as early as
two hours following TRAIL treatment (Figure 2b). Activity
of the executioner caspases 3 and 7 were also assessed
after 24 hours of TRAIL treatment. Consistent with the
caspase-8 findings, silencing Siah2 or POSH led to an
increase in caspase-3/7 activity (Figure 2c). These results
confirm our screening data and reveal Siah2 and POSH as
two E3 ubiquitin-ligase enzymes that can regulate death
receptor-induced caspase activity.
Increased sensitivity to apoptosis induced by death
ligands following Siah2 or POSH silencing
To test the effect of silencing Siah2 on the susceptibility
to extrinsic apoptosis, PPC-1 cells were first transfected
with Siah2-specific siRNA or a non-targeting control for
72 hours. Next, cells were treated with or without
TRAIL and visualized by phase-contrast microscopy.
After 10 hours, Siah2 targeting led to prominent apop-
totic morphological characteristics (i.e. membrane bleb-
bing, cell shrinkage and loss of adherence) in response
to TRAIL (Figure 3a). To quantify viability, a colori-
metric MTT assay was performed on the same set of
cells 24 hours after TRAIL treatment. Cells in which
Siah2 was targeted were significantly more susceptible
to TRAIL-induced cell death than non-targeting siRNA
control cells as shown by the decrease in cell viability by
approximately 50% (Figure 3b).
To test if the observed differences in cell viability were
due to the induction of apoptosis, annexin V staining
was carried out. PPC-1 cells were transfected with Siah2
or non-targeting siRNA. Following a 72-hour incuba-
tion, TRAIL was added to the media for 16 hours. Cells
were then stained with annexin V and propidium iodide
and subjected to flow cytometry to identify the viable,
annexin V positive cell population (Figure 3c). Siah2
silencing led to a marked induction of annexin positive
cells compared to the non-targeting control (Figure 3d).
The ability of Siah2 knockdown to enhance TRAIL-
induced apoptosis was confirmed using a unique siRNA
that targeted the 3’-UTR (Additional File 1). Consistent
with the observation that targeting Siah2 increases cas-
pase-8 activity, these findings demonstrate that Siah2
can regulate TRAIL-mediated apoptosis.
To further assess the impact of silencing Siah2 or
POSH on both TRAIL and Fas ligand-mediated apopto-
sis the PC-3 cell line was used. After siRNA-mediated
knockdown of Siah2 or POSH, either TRAIL was added
or cells were transfected with a Fas ligand (FasL) expres-
sing construct. Following 16-hour incubation with
TRAIL or 24 hours post-transfection, annexin V staining
was performed. In PC-3 cells containing diminished
Siah2 or POSH levels, stimulation with TRAIL or FasL
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Figure 2 Silencing of Siah2 or POSH enhances caspase activity
in response to TRAIL. a: qRT-PCR assessment of Siah2 and POSH
targeting in PC-3 and PPC-1 cells 24 hours after siRNA transfection.
b: Caspase-8 activity in PC-3 cells transfected with siRNA specific for
Siah2 or POSH for 72 hours and treated with TRAIL (100 ng/mL) for
2 and 4 hours. c: Caspase-3/7 activity in PC-3 cells treated as in
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lead to a 4-fold and 2-fold increase in apoptosis, respec-
tively, as compared to non-targeting siRNA control cells
(Figure 3e). These data identify Siah2 and POSH as nega-
tive regulators of death receptor-mediated apoptosis.
RING-domain function is required for the anti-apoptotic
activity of Siah2 but not POSH
Targeting Siah2 and POSH enhanced sensitivity to
apoptosis. This could be due to either downregulation
of protein expression or loss of enzymatic activity. To
discern between these two possibilities we generated
RING mutant versions of Siah2 (rmSiah2) and POSH
(rmPOSH). RING-finger domains bind to ubiquitin-con-
jugating enzymes. This association brings a substrate in
close proximity to the ubiquitin-conjugated E2. RING
domains feature a distinct cross-brace motif in which
conserved cysteine and histidine residues coordinate two
zinc atoms [12]. Mutating a cysteine and histidine
within the cross-brace abrogates E3 function by prevent-
ing association with an ubiquitin-charged E2. For Siah2,
we used site-directed mutagenesis to generate H98A/
C101A mutations and stably expressed the rmSiah2
construct (Figure 4a, inset). PC-3 cells stably expressing
rmSiah2 or the vector only were treated with TRAIL
(100 ng/mL) for 16 hours and analyzed for apoptosis
induction. Inhibiting Siah2 RING function led to an
increased sensitivity to TRAIL-mediated apoptosis as
compared to empty vector control cells (Puro) (Figure
4a). In contrast, rmPOSH had no effect on TRAIL-
induced cell death (Additional File 2). These data
suggest that the enzymatic function of Siah2 and the
protein levels of POSH are responsible for their ability
to regulate apoptosis.
Siah2 functions downstream of caspase-8 processing
To begin to identify where in the apoptotic pathway
Siah2 functions, the effect of Siah2 expression on procas-
pase-8 processing was examined. PPC-1 cells were trans-
fected with siRNA to silence Siah2 or a non-targeting
control sequence. After 72 hours, cells were treated with
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TRAIL and procaspase-8 processing was monitored by
Western blot analysis. Cells transfected with non-targeting
siRNA and treated with TRAIL showed a decrease in
procaspase-8 abundance and a corresponding increase in
the catalytically active p18 subunit. p18 subunit abun-
dance was highest eight hours after treatment and
decreased over 16 hours. Similar procaspase-8 processing
kinetics was observed in Siah2 knockdown cells
(Figure 4b, left). However, silencing of Siah2 in PPC-1
cells leads to an increase in caspase-8 activity upon
TRAIL stimulation (Figure 4b, right). These data imply
that Siah2 does not function to regulate procaspase-8
processing, but rather mediates its effects further down-
stream in the apoptotic pathway.
As Siah2 silencing was enhancing caspase-8 activity
downstream of DISC processing we hypothesized that
this E3 may also affect cell death outside of the extrinsic
pathway. Therefore, its ability to impact cell death
induced by other agents was investigated. PC-3 cells in
which Siah2 was targeted were treated with various
agents that induce apoptosis through multiple pathways
and the effect on apoptosis was quantified. Although
not as robust as when exposed to TRAIL, Siah2 silen-
cing resulted in sensitization to doxorubicin and thapsi-
gargin (Figure 4c). In contrast, POSH silencing only
sensitized cells to extrinsic death stimuli (Figure 4c).
These data demonstrate that agents that function inde-
pendent of the extrinsic pathway also achieve apoptosis
induction following Siah2 silencing.
Sub-cellular localization was performed to gain further
insight into where Siah2 and POSH may function. Pro-
tein from PPC-1 cells stably overexpressing rmSiah2-
myc or POSH-myc was harvested and subjected to frac-
tionation. Siah2 and POSH were present only in the
cytoplasmic fractions and their presence was unaltered
upon TRAIL stimulation (Figure 4d). Cytosolic localiza-
tion was confirmed by immunocytochemistry and confo-
cal microscopy. Confocal analysis revealed Siah2 to be
primarily cytoplasmic with an intense punctuate, granu-
lar staining pattern reminiscent of the 26S proteasome
(Figure 4e). Subsequent immunocytochemistry per-
formed in conjunction with anti-20S proteasome anti-
sera revealed high levels of co-localization (Figure 4e).
As these localization experiments utilize the overexpres-
sion of a tagged construct, it is possible that endogenous
Siah2 is not localized in the same exact manner. How-
ever, these data suggest Siah2 is acting to inhibit cell
death downstream in the apoptotic pathway, possibly
mediating its function at the proteasome.
Siah2/POSH interaction
Surprisingly, it has been demonstrated that POSH, in an
E3-independent fashion, interacts with Siah2 and can
stabilize Siah proteins [13]. To verify this interaction, a
yeast two-hybrid assay was employed. The AH-109 yeast
strain was co-transformed with full length POSH
Gal4-DNA binding-domain fusion construct (pGBKT7-
POSH) and wild type Siah2 GAL4-activation-domain
fusion construct (pACT-Siah2) or empty vector controls.
Although all co-transformants grew on +Ade+His plates,
only those co-transformed with constructs expressing
both POSH and Siah2 grew on the -Ade-His indicating
an interaction has occurred (Figure 5a). To verify an
interaction between Siah2 and POSH PPC-1 cells stably
expressing wtPOSH-myc were transiently transfected
with rmSiah2-HA or caspase-8 p30-HA as a negative
control. Co-immunoprecipitation using anti-myc conju-
gated magnetic beads revealed rmSiah2 present in the
wtPOSH-myc precipitate but not p30-HA (Figure 5b)
To determine where Siah2 was binding to POSH, several
POSH deletion mutants containing individual or combina-
tions of SH3-domains were generated (Figure 5c) and a
yeast two-hybrid mapping analysis was performed. As
shown in Figure 5c, only the yeast transformants contain-
ing the POSH spacer region between SH3-3 and SH3-4
could bind to Siah2 and induce reporter gene transcrip-
tion. In fact, the spacer region of POSH alone was suffi-
cient to induce POSH/Siah2 binding. Interestingly, a
known Siah2 substrate binding motif (RPxAxVxP) is pre-
sent within the spacer region and could be mediating
POSH binding to Siah2. Yeast transformants expressing
wtSiah2 in combination with a 19AA portion of the POSH
spacer region containing the Siah2 binding motif (POSH-
19mer) also grew on -Ade-His suggesting POSH binds the
C-terminal substrate binding domain of Siah2. To further
validate this finding, a POSH construct was generated in
which two key residues within the Siah2 binding domain
were mutated (POSH-spacer-NTN). Mutating the sus-
pected Siah2 binding domain within the POSH spacer
region abolished POSH/Siah2 interaction (Figure 5c) and
confirmed POSH binding to the substrate binding domain
of Siah2.
Conclusion
The primary finding presented here is the ability of two
E3 ubiquitin ligases to weaken signaling through the
death receptor apoptotic pathway. By utilizing RNA
interference technologies we have successfully estab-
lished Siah2 and POSH as two UPS components that
can reduce caspase activity in response to death ligands
in prostate cancer cells.
Siah2 is a homolog of the Drosophila Sina gene, a critical
component in photoreceptor development. The protein
contains an N-terminal RING-finger domain which
provides E3 ubiquitin ligase activity. The RING-domain is
followed by two zinc finger-domains and a C-terminal
substrate binding-domain [14]. Current literature provides
evidence for Siah2 function in the hypoxic response.
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One proposed mechanism is by regulating HIF-1a protein
levels by the ubiquitination and subsequent degradation of
PHD3 (prolyl hydroxylating domain-containing 3), a prolyl
hydroxylase that controls HIF-1a accumulation in hypoxic
environments [15]. A second possible hypoxia regulatory
point is through the degradation of HIP2K (homeodo-
main-interacting protein kinase 2), a member of the HIPK
family of proline-directed kinases [16]. Under normoxia,
the ability of Siah2 to modulate cell proliferation in lung
cancer cells has been detailed [17]; a finding we have con-
firmed in prostate cancer cells (Additional File 3).
POSH (plenty of SH3s) is a large scaffold molecule
containing an N-terminal RING-finger domain followed
by four SH3-domains and a region known to bind Rac1-
GTP. The RING-domain has been shown to display ubi-
quitin ligase activity and is thought to regulate trans-
Golgi network transport [18]. The scaffolding function
of POSH is most closely associated with c-Jun N-term-
inal kinase signaling [19]. Although multiple investiga-
tors have reported transient POSH overexpression can
induce apoptosis [19,20], we did not observe death in
our prostate cancer models upon lower, stable expres-
sion (data not shown). Conversely, we have shown that
down regulation of POSH can sensitize cells to TRAIL-
dependent apoptosis induction.
Providing mechanistic data to explain Siah2-dependent
apoptosis regulation is ongoing. Initial Siah2 characteri-
zations in the death receptor pathway have revealed
clues to possible mechanisms. As shown in Figure 4a,
the E3 activity of Siah2’s RING-domain is required for
its anti-apoptotic function, suggesting the E3 ligase
enzymatic activity is responsible for the degradation of a
pro-apoptotic protein. Proposed Siah2 substrates include
TRAF2, PHD3 and HIPK2 [15,16,21]. We have failed to
pACT + pGBKT7
pACT-Siah2 + pGBKT7
pACT + pGBKT7-POSH
pACT-Siah2 + pGBKT7-POSH
+Ade +His -Ade -His
POSH-SH1
POSH-SH2
POSH-SH3
RING SH3-1 SH3-2 SH3-3 SH3-4
AAHNQERPTAAVTPIQVQN
594 612
FL-POSH
600 607
506 829
POSH-SH3+Spacer
POSH-Spacer
POSH-19mer
POSH-Spacer (NTN)
a b
-Ade -His
YES
NO
NO
NO
YES
YES
YES
NO
30
80
kDa
p30-HA
rmSiah2-HA
wtPOSH-myc
wtPOSH-myc
rmSiah2-HA
p30-HA
+ + + +
+ +
+ +
_ _
_ _
Input myc-IP
c
FL-POSH
Figure 5 Physical interaction between POSH and Siah2. a: The AH-109 yeast strain was co-transformed with full length POSH Gal4-DNA-
binding-domain fusion construct (pGBKT7-POSH) and wild type Siah2 GAL4-activation-domain fusion construct (pACT-Siah2) or empty vector
controls. Transformants were grown on plates supplemented with (+Ade+His) or without (-Ade-His) adenine and histidine. -Ade-His is the yeast-
medium-plate lacking Leu, Trp, His and Ade in which activation of the adenine and histidine reporter gene is being tested. +Ade+His is the
yeast-medium-plate lacking Leu and Trp, selecting only for presence of plasmids being tested for interaction. b: PPC-1 cells stably expressing
POSH-myc were transfected with rmSiah2-HA or caspase-8 p30 as a negative control and co-immunoprecipitation using anti-myc conjugated
magnetic beads was performed. The anti-myc immune complexes were analyzed for the presence of Siah2-myc via Western blot. c: Schematic
representation of full length POSH (top) and various mutants cloned into the pGBKT7 vector. The yeast strain AH-109 was co-transformed with
pACT-Siah2 and the various POSH mutants and grown on +Ade+His or -Ade-His plates. YES/NO indicates the presence or absence of colonies
on -Ade-His plates (left).
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confirm the interaction with PHD3 or TRAF2 or Siah2-
mediated regulation of NF-B activity in our prostate
models (data not shown). However, the recently identi-
fied pro-apoptotic, Siah2-specific substrate HIPK2 is a
promising candidate. HIPK2 is a serine/threonine kinase
known to phosphorylate p53 at serine 46, thereby pro-
moting p53 acetylation and p53-dependent gene expres-
sion [22]. Inhibition of HIPK2 has been shown to
protect lung cancer cells against UV-induced apoptosis
while overexpression of HIPK2 sensitizes cells to UV-
induced apoptosis and decreases cell proliferation
[22,23]. Together, these data suggest a possible scenario
in which Siah2 targeting of HIPK2 protects cancer cells
from apoptosis induction while inhibition of Siah2 could
increase HIPK2 abundance thus sensitizing cancer cells
to cell death agents.
Regulation of cell death by Siah2 was found to be
selective, but not specific for the death receptor path-
way. This finding, along with data demonstrating Siah2
silencing induces caspase-8 activity without altering pro-
caspase-8 processing, suggested to us that Siah2 was act-
ing further downstream in the death receptor pathway.
Cellular localization analysis of Siah2 revealed a predo-
minately cytoplasmic staining pattern, consistent with
previous reports [16,24]. High levels of Siah2 co-locali-
zation with the 20S core proteasome was also observed
and may provide insight into Siah2’s regulation of cell
death. Interestingly, several E3-ligases such as Hul5, Par-
kin, Ubr1, and VHL are known to localize to complexes
in association with the 26S proteasome [25], adding
validity to this novel finding.
In contrast to Siah2, the ability of POSH to regulate
apoptosis induction in response to TRAIL was indepen-
dent of E3 activity, suggesting protein-protein interac-
tions (possibly mediated through one of four SH3-
domains) are important for this activity. Surprisingly, it
has been demonstrated that POSH in an E3-indepen-
dent fashion interacts with Siah2 and can stabilize Siah
proteins [13]. We have successfully confirmed a physical
interaction between E3 ligases Siah2 and POSH. By uti-
lizing a yeast-two-hybrid mapping approach we have
defined the spacer region of POSH, more specifically the
RPxAxVxP Siah2 substrate binding motif encompassing
amino acids 601-607, to be the site of Siah2 binding.
POSH has been shown to bind both Siah1 and Siah2
suggestive of possible overlapping, POSH-dependent
functions of these two E3s. The RPxAxVxP motif within
POSH is highly conserved from Xenopus to humans
suggesting a Siah-POSH binding event is critical for the
proper function of a highly conserved biochemical path-
way. Taken together, the ability of Siah2 to interact with
such a large signaling molecule such as POSH, as well
as its capacity to dimerize, could provide opportunities
for Siah2 to be recruited to key protein signaling
complexes where it can carry out its E3 ligase function.
For example, monomeric Siah2 could be recruited to
signaling complexes via a degradation-independent
interaction with POSH. Free monomeric Siah2 could
then associate with the complex through dimerization.
POSH, through one of four SH3 domains, could recruit
possible target substrates allowing Siah2 to carry out its
polyubiquitination/degradation function.
As Siah2 and POSH suppress cell death, their upregu-
lation may be advantageous in cancer cells. We, there-
fore, speculated that these E3s would be overexpressed
in a subset of cancers. Oncomine analysis revealed Siah2
to be significantly overexpressed in both B-cell acute
lymphoblastic leukemia [26] and squamous non-small-
cell lung carcinoma [27], while POSH is one of the
most frequently overexpressed genes in prostate cancer
[28-30]. At this point, however, there is no evidence
that either gene is capable of cellular transformation.
Together, these data suggest that development of sec-
ond generation proteasome inhibitors that block E3 ubi-
quitin ligases, such as Siah2 and POSH, could be
beneficial for cancer treatment. Recently, major
advances in targeted E3 therapies for the intrinsic apop-
totic pathway have been made. Most notably, generation
and characterization of Smac mimetic compounds that
inhibit IAP function. Smac mimetic compounds have
been shown to sensitize cancer cells to chemotherapeu-
tic agents as wells as strongly enhance the anti-tumor
activity of death ligands such as TRAIL in vivo [6]. It
remains to be tested if targeting of the extrinsic apopto-
tic pathway via Siah2 or POSH inhibition in combina-
tion with current intrinsic targeting compounds is a
promising cancer therapeutic strategy.
Methods
Cell Culture and Reagents
All prostate cancer cell lines were obtained from ATCC
(Manassas, VA) and grown in DMEM containing 10%
FBS. Velcade (Millenium Pharmaceuticals, Cambridge,
MA) was donated by the University of Kentucky, Mar-
key Cancer Center Pharmacy. The GST-TRAIL fusion
protein was purified by affinity chromatography as
described [31]. Fas ligand was expressed in cells as
described [10]. Staurosporine, doxorubicin and thapsi-
gargin were purchased from EMD Biosciences (San
Diego, CA).
Cell Viability, Apoptosis and Proliferation Assays
Cell viability was measured using a colorimetric MTT
assay. Media was removed from the cells and a 1 mg/ml
solution of thiazolyl blue tetrazolium bromide (MTT)
(Alfa Aesar, Ward Hill, MA) in 1 × PBS was added. The
samples were read on a spectrophotometer at 570 nm
minus 690 nm. All assays were conducted in replicates
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of four to six. Annexin V staining was carried out as
described by the manufacturer (Invitrogen, Carlsbad,
Ca). Cells were immediately analyzed by flow cytometry
(FACSCalibur, BD Immunocytometry Systems, San Jose,
CA). CellQuest Pro software (BD Immunocytometry
Systems) was used to quantify percentage of annexin V
positive and viable cells in 20,000 gated events.
BrdU labeling and flow cytometric analysis was carried
out as previously described [32]. The percentage of
BrdU positive cells (10,000 gated events) was deter-
mined using CellQuest software (BD). All assays were
carried out in replicates of three. All statistical assess-
ments were made using a Student’s t-test.
Western Blot Analysis
Cell lysates were prepared in ubiquitin protein extrac-
tion buffer (UPEB; 150 mM NaCl, 50 mM Tris-HCl (pH
7.5), 5 mM EDTA, 1% (v/v) NP-40, 0.1% (w/v) SDS,
0.5% (w/v) sodium deoxycholate). Western blot analysis
was carried out as previously described [33]. Antibodies
were obtained from the following sources: b-actin
(Sigma, St. Louis, MO), caspase-8, 1C12 (Cell Signaling
Technology, Danvers, MA), myc, 9B11 (Cell Signaling
Technology), cytochrome-C (Santa Cruz Biotechnology,
Santa Cruz, CA), PDI (Stressgene, Ann Arbor, MI).
Caspase Activity
In vivo caspase-8 activity was measured with the lumi-
nescent-based Caspase-Glo 8 Assay kit while caspase-3/
7 activity was measured by the addition of the lumines-
cent-based Caspase-Glo 3/7 Assay kit (Promega, Madi-
son, WI). At 16 hr post-treatment, three wells in each
treatment group were pre-incubated for 30 min with the
cell permeable caspase-8 inhibitor Z-IETD-fmk or the
pan caspase inhibitor Z-VAD fmk (25 mM, R&D Sys-
tems, Minneapolis, MN). Each treatment group con-
sisted of seven wells, four without fmk inhibitor and
three with the inhibitor. The Caspase-Glo reagent was
added to the cells and activity measured with a Lmax
luminometer (Molecular Devices Corporation, Sunny-
vale, CA). Data was analyzed by SOFTmax Pro (Version
1.1L). Specific caspase activity was calculated by sub-
tracting the activity derived from cells treated with Z-
IETD/VAD-fmk.
E3-ligase siRNA Screen
The siARRAY E3 ubiquitin-ligase library containing 239
total E3 specific siRNAs was purchased from Dharma-
con (Lafayette, CO). The predispensed dehydrated
siRNA was first rehydrated with a solution of DMEM
containing DharmaFECT transfection reagent. DU145
cells (10,000) were seeded directly into the 96-well
plates containing the rehydrated siRNA. 48 hours after
siRNA transfection, cells were treated with GST-TRAIL
(50 ng/mL) for 16 hours. The addition of 50 mM Vel-
cade in combination with TRAIL served as a positive
control. Caspase-8 activity was measured as previously
discussed by the addition of Caspase-GLO 8 pro-lumi-
nescent reagent. All E3 ligase siRNA experiments were
performed in triplicate.
Quantitative Reverse-transcriptase PCR
DU145, PC-3 and PPC-1 cells were seeded into 6-well
tissue culture plates. Cells were transfected with non-tar-
geting siRNA or siRNA specific for Siah2 or POSH. 48
hours after siRNA transfection, RNA was harvested using
the RNeasy kit (Qiagen, Valencia, CA). cDNA was gener-
ated using SuperScript II Reverse Transcriptase (Invitro-
gen). qRT-PCR was carried out using primer sets for 18S,
Siah2 or POSH in the presence of FastStart Universal
SYBR Green Master Mix (Roche, Nutley, NJ). PCR was
performed and analyzed using a 4300 Real Time PCR
System (Applied Biosystems, Foster City, CA). Percent
mRNA remaining was determined by the comparative CT
method (ΔCT) for relative quantification.
E3 Ubiquitin-Ligase Cloning and Expression
Wild-type human Siah2 (NM_0056067) and RING
mutant Siah2 (H98A, C101A) were generated by PCR,
cloned into a retroviral pBabe puro expression vector
(Addgene, Cambridge, MA) and verified by sequence
analysis. Retrovirus was generated as previously
described [34] and added to PC-3 and PPC-1 cells for
24 hours. Cells were selected by treatment with 2 μg/
mL of puromycin (EMD Biosciences, San Diego, CA).
Selection was carried out for one week and expression
was confirmed by Western blotting. Similarly, wild-type
POSH (NM_020870) and RING mutant POSH (H28A,
C30A) were generated.
Sub-cellular Fractionation
Cytoplasmic, microsomal and mitochondrial fractions
were obtained from PPC-1 cells stably overexpressing
rmSiah2-myc using the Qproteome Mitochondria Isola-
tion Kit (Qiagen). Cells were first treated +/- GST-
TRAIL (100 ng/mL) for 2 hours. Cells were collected
and protein harvested in provided lysis buffer. The cyto-
plasmic fraction was obtained by centrifuging total cell
lysate at 1000 × g for 10 min at 4°C and the collecting
supernatant. Nuclei and unbroken cells were collected
by pelleting lysate in the disruption buffer at 1000 × g
for 10 min at 4°C. A microsomal fraction was obtained
by centrifugation of protein lysate (in disruption buffer)
at 6000 × g for 10 min at 4°C. Finally, the mitochondrial
fraction was collected in provided mitochondrial purifi-
cation buffer by sequential centrifugation at 14,000 × g
for 15 min then 8000 × g for 10 min both at 4°C. The
purified mitochondrial pellet was resuspended in the
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provided mitochondrial storage buffer. 50 μg of each
fraction was added to SDS loading buffer and Western
blot analysis was performed.
Immunocytochemistry
PPC-1 cells stably expressing rmSiah2-myc were seeded
into 4-well chamber slides. Cells were fixed with 4%
paraformaldehyde for 20 minutes and permeabilized
with saponin (1 mg/mL) in Hank’s Buffered Saline Solu-
tion for 15 minutes. Following blocking in 2% BSA for
30 minutes, primary antibodies were added for 1 hour
followed by PBST washing. Fluorescently conjugated
secondary antibodies were added for 45 minutes. Slides
were mounted in Vectashield + DAPI (Vector Labora-
tories, Burlingame, CA) and visualized by a Leica TSP
SP5 confocal microscope. Antibodies were obtained
from the following sources: myc, 9B11 (Cell Signaling
Technology), 20S proteasome core subunits (Calbio-
chem, San Diego, CA).
Myc-POSH Immunoprecipitation
Cells expressing myc-tagged constructs were incubated
at 37°C for 48 hrs. Protein was harvested in IP buffer
(10 mM Tris pH 7.4, 1% Triton X-100, 0.5% NP-40, 150
mM NaCl, 20 mM NaF, 1 mM EDTA) and incubated
on ice for 30 min. Cell debris was pelleted by centrifu-
gation at 10,000 × g for 15 min at 4°C. 50 μl μMACS
anti-myc MicroBeads (Miltenyi Biotech, Auburn, CA)
was added to the lysate and incubated on ice for
30 min. myc-POSH was purified by passing cell lysate +
microbeads through a μMACS column attached to the
μMACS magnetic Separator. Column was washed with
800 μl IP buffer and protein was eluted by adding 20 μl
pre-heated (95°C) elution buffer (provided), incubating
for 5 min and adding another 50 μl elution buffer.
Eluted protein was subjected to SDS-PAGE followed by
Western blot analysis.
Yeast Two-Hybrid
Full length POSH was cloned into pGBKT7 (Clontech,
Mountain View, CA) as a Gal4-DNA-binding domain
fusion. Full length Siah2 as cloned into pACT2 (Clon-
tech) as a Gal4-Activiation domain fusion. The fusion
constructs or empty vector controls were co-trans-
formed into the AH-109 yeast strain. Briefly, a single
colony of AH-109 yeast (Clontech) was inoculated into
5 mL liquid YPD and incubated overnight at 30°C. The
overnight culture was inoculated into 50 mL liquid YPD
and allowed to grow to a cell density of 2 × 107 cell/mL.
The 50 mL culture was harvested by centrifugation at
3000 × g for 5 min. Yeast were resuspended in 1 ml of
100 mM LiAc. Cells were pelleted at 10,000 rpm in a
table top centrifuge for 5 sec and the LiAc was removed.
Yeast cells were resuspended to a final cell density of
2 × 109 cells/mL in 100 mM LiAc. 50 μl of resuspended
yeast were used per co-transformation. A transformation
mix containing 240 μl PEG (Bainbridge Island, WA)
(50% w/v), 36 μl 1.0 M LiAc, 25 μl single stranded DNA
(2.0 mg/mL), plasmid DNA (2 μg per construct) and
ddH2O up to 350 μl was made. The transformation mix
was added directly to the resuspended yeast, vortexed
and incubated at 30°C for 30 min. Yeast were heat
shocked at 42°C for 25 min and microcentrifuged at
8,000 rpm for 15 sec. Transformation mix was removed
and yeast were resuspended in 400 μl ddH2O. Trans-
formed yeast were plated onto selective agar plates (200
μl per plate).
Additional material
Additional file 1: Targeting Siah2 by a second independent siRNA
enhances apoptosis in response to TRAIL. (left) qRT-PCR confirmation
of Siah2 targeting in PC-3 cells using a Siah2 3’UTR specific siRNA pool.
(right) Annexin V staining of Siah2 3’UTR targeted PC-3 cells treated with
TRAIL for 16 hours (100 ng/mL). **P < 0.01, ***P < 0.001.
Additional file 2: RING mutant POSH expression does not affect
sensitivity to TRAIL-mediated apoptosis. PPC-1 cells stably expressing
rmPOSH were treated with TRAIL for 16 hours (100 ng/mL) and annexin
V stained to determine percent apoptosis. All values indicate the mean
percent annexin V positive cells +/- the standard deviation.
Additional file 3: Cellular proliferation is decreased upon Siah2
silencing. PC-3 cells were transfected with siRNA to target Siah2. Cells
were BrdU labeled 72 hours later. The percentage of BrdU positive cells
was determined by flow cytometry. All values indicate the mean BrdU
positive cells (N = 3) +/- the standard deviation. ***P < 0.001.
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